Kiniksa Pharmaceuticals, Ltd. (KNSA) Bundle
Understanding Kiniksa Pharmaceuticals, Ltd. (KNSA) Revenue Streams
Understanding Kiniksa Pharmaceuticals, Ltd. (KNSA)’s Revenue Streams
Product Revenue: For the three months ended September 30, 2024, net revenue from the sale of ARCALYST was $112.2 million, compared to $64.8 million for the same period in 2023, marking an increase of $47.4 million. For the nine months ended September 30, 2024, net revenue was $294.5 million, up from $162.0 million in 2023, reflecting a year-over-year increase of $132.5 million.
License and Collaboration Revenue: For the three months ended September 30, 2024, there was no license and collaboration revenue, compared to $2.2 million for the same period in 2023. For the nine months ended September 30, 2024, license and collaboration revenue was $6.2 million, down from $24.9 million in 2023, a decrease of $18.7 million.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for total revenue for the nine months ended September 30, 2024, was approximately 60.9%, increasing from $186.9 million in 2023 to $300.7 million in 2024.
Revenue Contribution by Segment
| Revenue Source | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) | Change (in millions) |
|---|---|---|---|---|---|---|
| Product Revenue | $112.2 | $64.8 | $47.4 | $294.5 | $162.0 | $132.5 |
| License and Collaboration Revenue | $0.0 | $2.2 | ($2.2) | $6.2 | $24.9 | ($18.7) |
| Total Revenue | $112.2 | $67.0 | $45.2 | $300.7 | $186.9 | $113.8 |
Analysis of Significant Changes in Revenue Streams
The primary driver of revenue growth has been the increase in product revenue from ARCALYST, attributed to a growing patient base. Conversely, the decline in license and collaboration revenue reflects the absence of significant milestones achieved in the current year compared to the previous year. The notable increase in product revenue for the nine months ended September 30, 2024, of $132.5 million compared to the prior year underscores the effectiveness of sales strategies and market penetration efforts.
For the nine months ended September 30, 2024, the cost of goods sold was $43.0 million, up from $23.8 million in 2023, indicating a $19.2 million increase, which correlates with the higher sales volume of ARCALYST.
Conclusion on Revenue Performance
As of September 30, 2024, Kiniksa Pharmaceuticals has demonstrated significant revenue growth driven mainly by its product sales, while experiencing a shift in revenue dynamics with a drop in collaboration revenue. The financial data reflects a robust operational strategy focused on expanding the market presence of ARCALYST.
A Deep Dive into Kiniksa Pharmaceuticals, Ltd. (KNSA) Profitability
A Deep Dive into Kiniksa Pharmaceuticals' Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit was calculated as follows:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Product Revenue, Net | $294,493,000 | $161,956,000 | $132,537,000 |
| Cost of Goods Sold | $43,014,000 | $23,823,000 | $19,191,000 |
| Gross Profit | $251,479,000 | $138,133,000 | $113,346,000 |
| Gross Profit Margin (%) | 85.4% | 85.2% | 0.2% |
Operating Profit: For the nine months ended September 30, 2024, the operating loss was:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Operating Expenses | $327,020,000 | $212,141,000 | $114,879,000 |
| Loss from Operations | $26,317,000 | $25,277,000 | $1,040,000 |
| Operating Margin (%) | -8.8% | -13.5% | 4.7% |
Net Profit Margin: For the nine months ended September 30, 2024, the net loss was:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Loss | $34,305,000 | $11,153,000 | $23,152,000 |
| Total Revenue | $300,703,000 | $186,864,000 | $113,839,000 |
| Net Profit Margin (%) | -11.4% | -6.0% | -5.4% |
Trends in Profitability: Comparing the three months ended September 30, 2024, with the same period in 2023:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Net Revenue | $112,214,000 | $67,046,000 | $45,168,000 |
| Net Loss | $12,693,000 | $13,855,000 | $1,162,000 |
| Operating Loss | $9,658,000 | $10,927,000 | $1,269,000 |
Industry Comparison: Profitability ratios compared with industry averages (as of 2024):
| Metric | Kiniksa Pharmaceuticals | Industry Average | Difference |
|---|---|---|---|
| Gross Margin (%) | 85.4% | 75.0% | 10.4% |
| Operating Margin (%) | -8.8% | -5.0% | -3.8% |
| Net Margin (%) | -11.4% | -8.0% | -3.4% |
Operational Efficiency: Key operational metrics for the nine months ended September 30, 2024:
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Cost of Goods Sold (COGS) | $43,014,000 | $23,823,000 | $19,191,000 |
| Research and Development Expenses | $76,408,000 | $56,045,000 | $20,363,000 |
| Selling, General and Administrative Expenses | $127,476,000 | $92,688,000 | $34,788,000 |
Debt vs. Equity: How Kiniksa Pharmaceuticals, Ltd. (KNSA) Finances Its Growth
Debt vs. Equity: How Kiniksa Pharmaceuticals Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, Kiniksa Pharmaceuticals reported total liabilities of $118.3 million, comprising both current and non-current liabilities. The breakdown includes:
- Current liabilities: $95.9 million
- Non-current liabilities: $22.4 million
Current liabilities include accounts payable of $8.3 million, accrued collaboration expenses of $29.1 million, and accrued expenses totaling $40.4 million.
Debt-to-Equity Ratio
The debt-to-equity ratio as of September 30, 2024, stands at 0.27. This is calculated using total liabilities of $118.3 million against total shareholders' equity of $437.0 million. This indicates that Kiniksa maintains a conservative approach to leveraging its growth compared to industry standards, where a typical ratio might hover around 0.5 to 1.0 for similar biopharmaceutical companies.
Recent Debt Issuances and Credit Ratings
Kiniksa has not engaged in significant new debt issuances recently. The company maintains a focus on equity financing and operational revenues. As of the latest reports, there are no specific credit ratings publicly available, but the company's liquidity as of September 30, 2024, was provided by cash, cash equivalents, and short-term investments totaling $223.8 million.
Balancing Debt Financing and Equity Funding
Kiniksa has primarily relied on equity financing to support its growth initiatives. The company raised $10.1 million through financing activities in the nine months ended September 30, 2024, primarily from the exercise of share options. This strategy reduces reliance on debt and mitigates financial risk while allowing for flexibility in funding operations and clinical trials.
| Financial Metric | Amount (in millions) |
|---|---|
| Total Liabilities | $118.3 |
| Current Liabilities | $95.9 |
| Non-current Liabilities | $22.4 |
| Total Shareholders' Equity | $437.0 |
| Debt-to-Equity Ratio | 0.27 |
| Cash, Cash Equivalents, and Short-term Investments | $223.8 |
| Financing Activities (9 months) | $10.1 |
Assessing Kiniksa Pharmaceuticals, Ltd. (KNSA) Liquidity
Assessing Kiniksa Pharmaceuticals' Liquidity
Current Ratio: As of September 30, 2024, the current ratio stands at 3.24, calculated from total current assets of $311.3 million and current liabilities of $95.96 million.
Quick Ratio: The quick ratio, excluding inventory, is approximately 2.26. This is derived from current assets of $311.3 million, less inventory of $28.68 million, divided by current liabilities of $95.96 million.
Working Capital Trends
Working capital, defined as current assets minus current liabilities, is $215.35 million as of September 30, 2024, indicating a healthy liquidity position. This represents a significant increase from $212.63 million at the end of 2023, reflecting a positive trend in managing short-term financial health.
Cash Flow Statements Overview
The following table summarizes cash flow trends for the nine months ended September 30, 2024, compared to the same period in 2023:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | $6,919 | $8,976 |
| Net Cash Used in Investing Activities | ($27,621) | ($14,663) |
| Net Cash Provided by Financing Activities | $10,124 | $800 |
| Net Decrease in Cash and Cash Equivalents | ($10,578) | ($4,887) |
Operating cash flows decreased from $8.98 million in 2023 to $6.92 million in 2024, primarily due to a drop in cash received from licensing agreements. Cash used in investing activities increased, reflecting a shift in portfolio management strategy.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company holds cash, cash equivalents, and short-term investments totaling $223.8 million. Despite this strong liquidity position, the company reported a net loss of $34.3 million for the nine months ended September 30, 2024, compared to a net loss of $11.2 million in the same period of the previous year. This trend raises potential liquidity concerns as ongoing operating losses may necessitate additional capital raises in the future.
Future obligations include minimum payments of $139.6 million under various agreements, of which $16 million is due within one year. The company’s ability to manage these obligations while maintaining liquidity will be critical in the coming periods.
Is Kiniksa Pharmaceuticals, Ltd. (KNSA) Overvalued or Undervalued?
Valuation Analysis
To assess the financial health of the company in 2024, we will look at various valuation metrics, stock price trends, and analyst consensus.
Price Ratios
The key valuation ratios for the company are as follows:
- Price-to-Earnings (P/E) Ratio: −37.53 (calculated from a net loss of $34.3 million and a share price of approximately $6.84 as of September 30, 2024)
- Price-to-Book (P/B) Ratio: 0.74 (based on a book value of $437 million and total shares outstanding of approximately 72.2 million)
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Not applicable due to negative EBITDA.
Stock Price Trends
The stock price has seen fluctuations over the past 12 months:
- 12-Month High: $12.50
- 12-Month Low: $5.00
- Current Price: $6.84 (as of September 30, 2024)
Dividend Yield and Payout Ratios
The company does not currently pay dividends; therefore, the dividend yield is 0% and the payout ratio is not applicable.
Analyst Consensus
Analyst consensus on stock valuation is mixed:
- Buy: 3 analysts
- Hold: 5 analysts
- Sell: 2 analysts
Financial Summary Table
| Metric | Value |
|---|---|
| P/E Ratio | −37.53 |
| P/B Ratio | 0.74 |
| EV/EBITDA Ratio | N/A |
| 12-Month High | $12.50 |
| 12-Month Low | $5.00 |
| Current Price | $6.84 |
| Dividend Yield | 0% |
| Analyst Consensus (Buy) | 3 |
| Analyst Consensus (Hold) | 5 |
| Analyst Consensus (Sell) | 2 |
Key Risks Facing Kiniksa Pharmaceuticals, Ltd. (KNSA)
Key Risks Facing Kiniksa Pharmaceuticals, Ltd.
Understanding the risk factors that impact a company's financial health is crucial for investors. For Kiniksa Pharmaceuticals, several internal and external risks pose significant challenges.
Industry Competition
The biopharmaceutical sector is characterized by intense competition. The company primarily competes with both established pharmaceutical companies and emerging biotech firms. As of September 30, 2024, the market dynamics indicate a growing number of competitors focusing on similar therapeutic areas, particularly in rare diseases. This competition could pressure pricing and market share, impacting revenues.
Regulatory Changes
Regulatory risk remains a key concern. The company’s operations are subject to regulations from the FDA, EMA, and other global health authorities. Any changes in regulatory policies or approval processes can significantly affect product development timelines and market entry strategies. In the nine months ended September 30, 2024, the company reported a net loss of $34.3 million, highlighting the financial impact of navigating these regulatory landscapes.
Market Conditions
Market conditions can also affect the company’s financial performance. Economic downturns or shifts in healthcare funding can reduce demand for the company’s products. The pharmaceutical market's overall growth rate is projected to be around 5% annually, but economic uncertainties could lead to fluctuations in sales forecasts.
Operational Risks
Operational risks include challenges in manufacturing and supply chain management. The company has committed to minimum payments of $139.6 million under various agreements for raw materials and services necessary for production. Disruptions in manufacturing or supply chains could lead to increased costs and delays in product availability.
Financial Risks
Financially, Kiniksa Pharmaceuticals has a history of operating losses, with an accumulated deficit of $512.3 million as of September 30, 2024. The net revenue from the sale of ARCALYST was $294.5 million for the nine months ended September 30, 2024, compared to $161.9 million for the same period in 2023, indicating reliance on a single product for revenue generation. Future revenue generation is subject to the successful commercialization of existing and new product candidates.
Strategic Risks
The company's strategic decisions, including partnerships and research directions, carry risks. Recent collaborations have led to milestone payments of $15 million and $5 million from Genentech for development achievements. However, the inability to achieve similar milestones in the future could jeopardize financial stability.
Mitigation Strategies
To address these risks, the company is focusing on enhancing its product pipeline and maintaining robust relationships with regulatory bodies. As of September 30, 2024, the company had cash, cash equivalents, and short-term investments totaling $223.8 million, providing a buffer to manage operational expenses and invest in growth opportunities.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Increased competition from established and emerging firms. | Pressure on pricing and market share. |
| Regulatory Changes | Changes in FDA and EMA regulations affecting product approvals. | Potential delays and increased costs. |
| Market Conditions | Economic downturns affecting healthcare funding. | Fluctuations in sales forecasts. |
| Operational Risks | Challenges in manufacturing and supply chain. | Increased costs and delays. |
| Financial Risks | History of operating losses and reliance on single product revenue. | Impact on financial stability. |
| Strategic Risks | Risks associated with partnerships and research directions. | Potential jeopardy to financial stability. |
Future Growth Prospects for Kiniksa Pharmaceuticals, Ltd. (KNSA)
Future Growth Prospects for Kiniksa Pharmaceuticals, Ltd. (KNSA)
Analysis of Key Growth Drivers
Key growth drivers for Kiniksa Pharmaceuticals include significant product innovations, market expansions, and strategic partnerships. The company's lead product, ARCALYST, generated net revenue of $112.2 million for the three months ended September 30, 2024, compared to $64.8 million for the same period in 2023, reflecting a growth of 73.1% year-over-year.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, Kiniksa reported total revenue of $300.7 million, compared to $186.9 million for the same period in 2023, an increase of $113.8 million or 60.9%. Analysts project continued growth in revenue driven by increasing patient adoption and potential new indications for ARCALYST, alongside the advancement of pipeline candidates like abiprubart and mavrilimumab.
Strategic Initiatives or Partnerships
Kiniksa's collaboration with Genentech remains a pivotal strategic initiative. The company received a milestone payment of $5.0 million in the second quarter of 2024 related to a new indication under the Genentech License Agreement. Additionally, the company has established partnerships that enhance its research and development capabilities, which are crucial for its pipeline growth.
Competitive Advantages
Kiniksa Pharmaceuticals benefits from distinct competitive advantages, including a robust intellectual property portfolio and strategic collaborations with industry leaders. The company had cash, cash equivalents, and short-term investments totaling $223.8 million as of September 30, 2024, providing a solid financial foundation to support ongoing and future development initiatives. Furthermore, Kiniksa's focus on niche therapeutic areas positions it favorably in the biopharmaceutical landscape.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Product Revenue, Net | $112.2 million | $64.8 million | +73.1% |
| Total Revenue | $300.7 million | $186.9 million | +60.9% |
| Net Loss | $34.3 million | $11.2 million | +207.1% |
| Cash, Cash Equivalents, and Short-term Investments | $223.8 million | N/A | N/A |
Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Kiniksa Pharmaceuticals, Ltd. (KNSA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Kiniksa Pharmaceuticals, Ltd. (KNSA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Kiniksa Pharmaceuticals, Ltd. (KNSA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.